Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Should Fine Companies With Late Post-Marketing Studies, HHS OIG Says

Executive Summary

FDA should have the authority to sanction pharmaceutical manufacturers that are not adequately fulfilling their post-marketing commitments, the HHS Office of Inspector General suggests

You may also be interested in...



FDA Postmarketing Study Oversight To Benefit From Informatics Upgrades

Changes in legacy DARRTS system, transition to new platform and standardized format for annual report submission should improve FDA's tracking of postmarketing requirements, agency tells Office of the Inspector General.

NDAs Supported By Foreign Data To Be Reviewed By HHS Inspector General

HHS' Office of Inspector General will examine how FDA handles the growing number of clinical trials being conducted overseas

NDAs Supported By Foreign Data To Be Reviewed By HHS Inspector General

HHS' Office of Inspector General will examine how FDA handles the growing number of clinical trials being conducted overseas

Related Content

UsernamePublicRestriction

Register

PS047385

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel